Drug Type Small molecule drug |
Synonyms Gumarontinib, Gumarontinib Hydrate, HH-SCC244 + [4] |
Target |
Action inhibitors |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (07 Mar 2023), |
RegulationOrphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China) |
Molecular FormulaC21H17N9O2S |
InChIKeyRYBLECYFLJXEJX-UHFFFAOYSA-N |
CAS Registry1642581-63-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
c-Met positive non-small cell lung cancer | Japan | 24 Jun 2024 | |
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer | China | 07 Mar 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR mutation MET positive Non-small Cell Lung Cancer | Phase 3 | China | 03 Apr 2025 | |
EGFR mutation MET positive Non-small Cell Lung Cancer | Phase 3 | China | 03 Apr 2025 | |
Non-Small Cell Lung Cancer | Phase 3 | China | 03 Apr 2025 | |
metastatic non-small cell lung cancer | Phase 2 | China | 11 May 2020 | |
metastatic non-small cell lung cancer | Phase 2 | China | 11 May 2020 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | China | 18 Nov 2019 | |
c-Met positive Adenocarcinoma of Esophagus | Phase 2 | China | 31 Jul 2019 | |
c-Met positive Adenocarcinoma of Esophagus | Phase 2 | China | 31 Jul 2019 | |
Pulmonary sarcomatoid carcinoma | Phase 2 | China | 31 Jul 2019 | |
Pulmonary sarcomatoid carcinoma | Phase 2 | China | 31 Jul 2019 |
Phase 2 | MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer MET Exon 14 Skipping | 84 | SCC244 300 mg once daily | hanmlacsxb(kkybjoulms) = adncjostez gcwodjaeyb (rlcdxnazvt, 54.3 - 76.1) View more | Positive | 07 Dec 2024 | |
SCC244 300 mg once daily (treatment-naïve) | hanmlacsxb(kkybjoulms) = thvlyxbikp gcwodjaeyb (rlcdxnazvt, 54.8 - 83.2) View more | ||||||
Phase 1/2 | c-Met positive non-small cell lung cancer MET Overexpression | 32 | ewfhsrxusz(hfqllushvl) = jbstazqshg gwxtrysfxc (klhfifzqmr, 63.6 - 92.8) View more | Positive | 01 Jan 2024 | ||
Phase 1/2 | 84 | rgklkkohch(paitamesms) = 32/84, 38% putaaeeoty (virumidggi ) View more | - | 01 May 2023 | |||
Phase 1 | 32 | zucbhedtpi(rvckoopmgw) = aoqjtwmjvf xhtavwwamd (ljbasqhgoj, 21.1 - 56.3) View more | Positive | 03 Dec 2022 | |||
(treatment naïve patients) | zucbhedtpi(rvckoopmgw) = hobddwkpdj xhtavwwamd (ljbasqhgoj, 15.2 - 72.3) | ||||||
Phase 2 | 30 | ntrlfbkhjw(ygbqkbngxv) = miicpqgkyn sxugxsqvyn (qkevmzbeip, [40.6 - 77.3]) View more | - | 03 Dec 2022 | |||
Phase 1 | Non-Small Cell Lung Cancer c-MET status | c-MET ex14 skipping mutation | c-MET IHC 3+ | 19 | ljpzdpbbkq(kzhpgojyua) = ucwlfqhcmq rjhbvmbjzf (pvzlcflwiw ) View more | - | 01 Mar 2021 | ||
Phase 1 | 18 | hhrfchjpmv(fojrfuvmza) = Peripheral edema (n = 1, 5.5%), hypothyroidism (n = 1, 5.5%) fxyivkitwh (hadqyumnqh ) View more | Positive | 25 May 2020 |